Document Detail

The effect of positive inotropes on the failing human myocardium.
MedLine Citation:
PMID:  9142430     Owner:  NLM     Status:  MEDLINE    
Heart failure is associated with pathobiochemical changes that can reduce the responsiveness of the myocardium to positive inotropic agents. We studied the contractile effects of a range of inotropic agents on papillary muscle strips from healthy and failing human hearts. Specimens were obtained from patients with different grades of heart failure. These included individuals undergoing mitral valve replacement (New York Heart Association Class II-III) or receiving heart transplantation (New York Heart Association Class IV). Heart failure was associated with attenuation of myocardial contractile responses to dobutamine, histamine, 3-isobutyl-1-methylxanthine, and the phosphodiesterase inhibitors, milrinone and pimobendan. However, pretreatment of the papillary muscle with isoprenaline augmented the positive inotropic effect observed with the phosphodiesterase inhibitors. The contractile response to ouabain was not influenced by the presence of heart failure. We conclude that, unlike beta-adrenoceptors, cardiac glycoside receptors in the myocardium are not down regulated in the presence of heart failure.
E Erdmann
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  Cardiology     Volume:  88 Suppl 2     ISSN:  0008-6312     ISO Abbreviation:  Cardiology     Publication Date:  1997  
Date Detail:
Created Date:  1997-07-10     Completed Date:  1997-07-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1266406     Medline TA:  Cardiology     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  7-11     Citation Subset:  IM    
Department of Internal Medicine, University of Cologne, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
1-Methyl-3-isobutylxanthine / pharmacology
Adrenergic beta-Agonists / pharmacology
Calcium / pharmacology
Cardiotonic Agents / pharmacology*
Dobutamine / pharmacology
Heart Failure / physiopathology*
Isoproterenol / pharmacology
Myocardial Contraction / drug effects*
Papillary Muscles / drug effects
Phosphodiesterase Inhibitors / pharmacology
Pyridazines / pharmacology
Pyridones / pharmacology
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Cardiotonic Agents; 0/Phosphodiesterase Inhibitors; 0/Pyridazines; 0/Pyridones; 28822-58-4/1-Methyl-3-isobutylxanthine; 34368-04-2/Dobutamine; 74150-27-9/pimobendan; 7440-70-2/Calcium; 7683-59-2/Isoproterenol; 78415-72-2/Milrinone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Current concepts in the treatment of congestive heart failure.
Next Document:  New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiester...